|
1
|
Huang PH, Xu AM and White FM: Oncogenic
EGFR signaling networks in glioma. Sci Signal. 2:re62009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guo G, Gong K, Wohlfeld B, Hatanpaa KJ,
Zhao D and Habib AA: Ligand-independent EGFR signaling. Cancer Res.
75:3436–3442. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gan HK, Cvrljevic AN and Johns TG: The
epidermal growth factor receptor variant III (EGFRvIII): Where wild
things are altered. FEBS J. 280:5350–5370. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gazdar AF: Activating and resistance
mutations of EGFR in non-small-cell lung cancer: Role in clinical
response to EGFR tyrosine kinase inhibitors. Oncogene. 28 (Suppl
1):S24–S31. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Taylor TE, Furnari FB and Cavenee WK:
Targeting EGFR for treatment of glioblastoma: Molecular basis to
overcome resistance. Curr Cancer Drug Targets. 12:197–209. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Padfield E, Hayley P and Kurian KM:
Current therapeutic advances targeting EGFR and EGFRvIII in
glioblastoma. Front Oncol. 5:52015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bethune G, Bethune D, Ridgway N and Xu Z:
Epidermal growth factor receptor (EGFR) in lung cancer: An overview
and update. J Thorac Dis. 2:48–51. 2010.PubMed/NCBI
|
|
8
|
An Z, Aksoy O, Zheng T, Fan QW and Weiss
WA: Epidermal growth factor receptor and EGFRvIII in glioblastoma:
Signaling pathways and targeted therapies. Oncogene. 37:1561–1575.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang J, Yan J and Liu B: Targeting
EGFRvIII for glioblastoma multiforme. Cancer Lett. 403:224–23.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arteaga CL and Engelman JA: ERBB
receptors: From oncogene discovery to basic science to
mechanism-based cancer therapeutics. Cancer Cell. 25:282–303. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gan HK, Kaye AH and Luwor RB: The EGFRvIII
variant in glioblastoma multiforme. J Clin Neurosci. 16:748–754.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tomas A, Futter CE and Eden ER: EGF
receptor trafficking: Consequences for signaling and cancer. Trends
Cell Biol. 24:26–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chistiakov DA, Chekhonin IV and Chekhonin
VP: The EGFR variant III mutant as a target for immunotherapy of
glioblastoma multiforme. Eur J Pharmacol. 810:70–82. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Keller S and Schmidt MHH: EGFR and
EGFRvIII promote angiogenesis and cell invasion in glioblastoma:
Combination therapies for an effective treatment. Int J Mol Sci.
18:12952017. View Article : Google Scholar
|
|
15
|
Sato K, Shin MS, Sakimura A, Zhou Y,
Tanaka T, Kawanishi M, Kawasaki Y, Yokoyama S, Koizumi K, Saiki I
and Sakurai H: Inverse correlation between Thr-669 and constitutive
tyrosine phosphorylation in the asymmetric epidermal growth factor
receptor dimer conformation. Cancer Sci. 104:1315–1322. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kawasaki Y, Sakimura A, Park CM, Tomaru R,
Tanaka T, Ozawa T, Zhou Y, Narita K, Kishi H, Muraguchi A and
Sakurai H: Feedback control of ErbB2 via ERK-mediated
phosphorylation of a conserved threonine in the juxtamembrane
domain. Sci Rep. 6:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Haryuni RD, Watabe S, Yamaguchi A, Fukushi
Y, Tanaka T, Kawasaki Y, Zhou Y, Yokoyama S and Sakurai H: Negative
feedback regulation of ErbB4 tyrosine kinase activity by
ERK-mediated non-canonical phosphorylation. Biochem Biophys Res
Commun. 514:456–461. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nishikawa R, Ji XD, Harmon RC, Lazar CS,
Gill GN, Cavenee WK and Huang HJ: A mutant epidermal growth factor
receptor common in human glioma confers enhanced tumorigenicity.
Proc Natl Acad Sci USA. 91:7727–7731. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nitta Y, Shimizu S, Shishido-Hara Y,
Suzuki K, Shiokawa Y and Nagane M: Nimotuzumab enhances
temozolomide-induced growth suppression of glioma cells expressing
mutant EGFR in vivo. Cancer Med. 5:486–499. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Y, Yamada N, Tanaka T, Hori T,
Yokoyama S, Hayakawa Y, Yano S, Fukuoka J, Koizumi K, Saiki I and
Sakurai H: Crucial roles of RSK in cell motility by catalysing
serine phosphorylation of EphA2. Nat Commun. 6:76792015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kinoshita E and Kinoshita-Kikuta E:
Improved Phos-tag SDS-PAGE under neutral pH conditions for advanced
protein phosphorylation profiling. Proteomics. 11:319–323. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lugowska I, Koseła-Paterczyk H, Kozak K
and Rutkowski P: Trametinib: A MEK inhibitor for management of
metastatic melanoma. Onco Targets Ther. 8:2251–2259.
2015.PubMed/NCBI
|
|
23
|
Najem A, Krayem M, Perdrix A, Kerger J,
Awada A, Journe F and Ghanem G: New drug combination strategies in
melanoma: Current status and future direction. Anticancer Res.
37:5941–5953. 2017.PubMed/NCBI
|
|
24
|
Li L, Chakraborty S, Yang CR, Hatanpaa KJ,
Cipher DJ, Puliyappadamba VT, Rehman A, Jiwani AJ, Mickey B, Madden
C, et al: An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop
regulates the activation of EGFRvIII. Oncogene. 33:4253–4264. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fan QW, Cheng C, Gustafson WC, Charron E,
Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, et
al: EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and
progression in glioblastoma. Cancer Cell. 24:438–449. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Luwor RB, Zhu HJ, Walker F, Vitali AA,
Perera RM, Burgess AW, Scott AM and Johns TG: The tumor-specific
de2-7 epidermal growth factor receptor (EGFR) promotes cells
survival and heterodimerizes with the wild-type EGFR. Oncogene.
23:6095–6104. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kwon SJ, Kwon OS, Kim KT, Go YH, Yu SI,
Lee BH, Miyoshi H, Oh E, Cho SJ and Cha HJ: Role of MEK partner-1
in cancer stemness through MEK/ERK pathway in cancerous neural stem
cells, expressing EGFRviii. Mol Cancer. 16:1402017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wee P and Wang Z: Epidermal growth factor
receptor cell proliferation. Cancers (Basel). 9:522017. View Article : Google Scholar
|
|
29
|
Li L, Puliyappadamba VT, Chakraborty S,
Rehman A, Vemireddy V, Saha D, Souza RF, Hatanpaa KJ, Koduru P,
Burma S, et al: EGFR wild type antagonizes EGFRvIII-mediated
activation of Met in glioblastoma. Oncogene. 34:129–134. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Puliyappadamba VT, Chakraborty S, Chauncey
SS, Li L, Hatanpaa KJ, Mickey B, Noorani S, Shu HK, Burma S,
Boothman DA and Habib AA: Opposing effect of EGFRWT on
EGFRvIII-mediated NF-κB activation with RIP1 as a cell death
switch. Cell Rep. 4:764–775. 2013. View Article : Google Scholar : PubMed/NCBI
|
